# EDGAR Filing Document

**Accession Number:** 0001819133
**File Stem:** 0001193125-25-291391
**Filing Date:** 2025-11
**Character Count:** 14711
**Document Hash:** fad9c8b1fd5d83214ffd3bfcd500d9fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-291391.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001193125-25-291391

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tango Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001819133
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92241
- **FILM NUMBER:** 251508146

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (857) 320-4900

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BCTG Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200723
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Third Rock Ventures IV, L.P.
- **CENTRAL INDEX KEY:** 0001688327

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE, 14TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** 617-585-2000

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE, 14TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Tango Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**87583X109**

*(CUSIP Number)*

**Third Rock Ventures, LLC**<br>201 Brookline Avenue<br>Suite 1401<br>Boston MA 02215<br>617-585-2000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **87583X109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Third Rock Ventures IV, L.P.** | Name of reporting person<br>**Third Rock Ventures IV, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7874574.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7874574.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.85%** | Percent of class represented by amount in Row (11)<br>**5.85%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.

| **CUSIP No.** | **87583X109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Third Rock Ventures GP IV, L.P.** | Name of reporting person<br>**Third Rock Ventures GP IV, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7874574.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7874574.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.85%** | Percent of class represented by amount in Row (11)<br>**5.85%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.

| **CUSIP No.** | **87583X109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TRV GP IV, LLC** | Name of reporting person<br>**TRV GP IV, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7874574.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7874574.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | Aggregate amount beneficially owned by each reporting person<br>**7874574.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.85%** | Percent of class represented by amount in Row (11)<br>**5.85%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Tango Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
201 Brookline Avenue, Suite 901, Boston, MA, 02215

This Amendment No. 3 (this "Amendment") amends and supplements the Schedule 13D (as amended, the "Schedule 13D") filed by the Reporting Persons with respect to the shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company" or the "Issuer"). The transactions described in Item 5(c) resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of November 19, 2025, TRV IV had shared voting and dispositive power with respect to 7,874,574 shares of the Issuer's Common Stock, constituting approximately 5.85% of the Issuer's outstanding Common Stock.

As of November 19, 2025, Third Rock Ventures GP IV, L.P. ("TRV GP IV"), as the general partner of TRV IV may be deemed to have shared voting and dispositive power with respect to all 7,874,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 5.85% of the Issuer's outstanding Common Stock.

As of November 19, 2025, TRV GP IV, LLC ("TRV GP IV LLC," and collectively with TRV IV and TRV GP IV, the "Reporting Persons"), as the general partner of TRV GP IV may be deemed to have shared voting and dispositive power with respect to all 7,874,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 5.85% of the Issuer's outstanding Common Stock.

The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on Novemebr 4, 2025.

**(b)**
Regarding the number of shares as to which such person has:

(i) sole power to vote or to direct the vote: See line 7 of cover sheets

(ii) shared power to vote or to direct the vote: See line 8 of cover sheets

(iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.

(iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets

**(c)**
Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended November 19, 2025.

                                  Date                          Amount of Securities                     Price per Share                                       Where and How Effected
TRV IV                     9/25/2025                      500,000                                       $8.02*                                                    Disposed in the Open Market
TRV IV                    10/23/2025                     477,401                                       $10.15*                                                  Disposed in the Open Market
TRV IV                     11/6/2025                      1,500,000                                    $8.00*                                                    Disposed in the Open Market
TRV IV                    11/10/2025                     278,956                                       $8.00*                                                    Disposed in the Open Market
TRV IV                    11/11/2025                     721,044                                       $8.20*                                                    Disposed in the Open Market
TRV IV                    11/12/2025                     1,512,000                                    $8.20*                                                    Disposed in the Open Market
TRV IV                    11/14/2025                     600,000                                       $8.20*                                                    Disposed in the Open Market
TRV IV                    11/17/2025                     14,875                                         $8.27*                                                    Disposed in the Open Market
TRV IV                    11/19/2025                     885,125                                       $8.26*                                                    Disposed in the Open Market
* The price reported is a weighted average price. These shares were sold in multiple transactions.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Third Rock Ventures IV, L.P.

**Signature:** /s/ Kevin Gillis

**Name/Title:** Kevin Gillis, COO of TRV GP IV, LLC, the general partner of Third Rock Ventures GP IV, L.P., the general partner of Third Rock Ventures IV, L.P.

**Date:** 11/21/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Third Rock Ventures GP IV, L.P.

**Signature:** /s/ Kevin Gillis

**Name/Title:** Kevin Gillis, COO of TRV GP IV, LLC, the general partner of Third Rock Ventures GP IV, L.P.

**Date:** 11/21/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TRV GP IV, LLC

**Signature:** /s/ Kevin Gillis

**Name/Title:** Kevin Gillis, COO

**Date:** 11/21/2025